{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:20:26Z","timestamp":1787674826008,"version":"build-2784847793"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.schres.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:30:48Z","timestamp":1621971048000},"page":"112-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment"],"prefix":"10.1016","volume":"232","author":[{"given":"Amanda J.","family":"Lisoway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement C.","family":"Zai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.schres.2021.05.010_bb0005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajmg.b.32361","article-title":"Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (dysbindin) promoter in saliva and post-mortem brain of patients with schizophrenia and psychotic bipolar disorder","volume":"168","author":"Abdolmaleky","year":"2015","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41380-018-0247-6","article-title":"Methylome-wide association findings for major depressive disorder overlap in blood and brain and replicate in independent brain samples","volume":"25","author":"Aberg","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2021.05.010_bb0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10673229.2012.747804","article-title":"Remission in schizophrenia: critical and systematic review","volume":"20","author":"AlAqeel","year":"2012","journal-title":"Harv. Rev. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/fcp.12424","article-title":"Dopamine (DRD2) and serotonin (HTR2A, 2C) receptor gene polymorphisms do not influence early response to risperidone in South Indian patients with schizophrenia","volume":"33","author":"Alladi","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/106002808902300201","article-title":"Clozapine: a novel antipsychotic agent","volume":"23","author":"Bablenis","year":"1989","journal-title":"DICP"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/gepi.21789","article-title":"Accounting for population stratification in DNA methylation studies","volume":"38","author":"Barfield","year":"2014","journal-title":"Genet. Epidemiol."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-014-3649-4","article-title":"Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia","volume":"232","author":"Bishop","year":"2015","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0045","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/npp.2015.5","article-title":"Variation in dopamine D2 and serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics","volume":"40","author":"Blasi","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.schres.2021.05.010_bb0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrg3273","article-title":"Analysing and interpreting DNA methylation data","volume":"13","author":"Bock","year":"2012","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0055","first-page":"613","article-title":"Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools","volume":"18","author":"Bousman","year":"2018","journal-title":"Pharm. J."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1176\/appi.ajp.2017.17101086","article-title":"Pharmacogenetic tests in psychiatry","volume":"175","author":"Bousman","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0149-7634(05)80058-2","article-title":"Clozapine: an atypical neuroleptic","volume":"14","author":"Bruhwyler","year":"1990","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0085","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.0.CO;2-U","article-title":"Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics","volume":"97","author":"Cardno","year":"2000","journal-title":"Am. J. Med. Genet."},{"issue":"Suppl. 10","key":"10.1016\/j.schres.2021.05.010_bb0095","first-page":"55","article-title":"The relationship of pharmacology to side effects","volume":"58","author":"Casey","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0100","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.neuron.2008.09.005","article-title":"Calcium channel regulation and presynaptic plasticity","volume":"59","author":"Catterall","year":"2008","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s11481-018-9811-8","article-title":"Prediction of schizophrenia diagnosis by integration of genetically correlated conditions and traits","volume":"13","author":"Chen","year":"2018","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The economic burden of schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0120","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/MCB.00607-10","article-title":"Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression","volume":"31","author":"de Carcer","year":"2011","journal-title":"Mol. Cell. Biol."},{"issue":"1\u20132","key":"10.1016\/j.schres.2021.05.010_bb0125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.psychres.2015.07.054","article-title":"Meta-analysis of dopamine receptor D1 rs4532 polymorphism and susceptibility to antipsychotic treatment response","volume":"229","author":"de Matos","year":"2015","journal-title":"Psychiatry Res."},{"issue":"24","key":"10.1016\/j.schres.2021.05.010_bb0130","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/hmg\/ddr416","article-title":"Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder","volume":"20","author":"Dempster","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/schbul\/sbs139","article-title":"Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future","volume":"39","author":"Dempster","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2021.05.010_bb0140","article-title":"Olanzapine for schizophrenia","volume":"2","author":"Duggan","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.schres.2021.05.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.171","article-title":"BECon: a tool for interpreting DNA methylation findings from blood in the context of brain","volume":"7","author":"Edgar","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0150","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/bioinformatics\/btu848","article-title":"PRSice: polygenic risk score software","volume":"31","author":"Euesden","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.schres.2021.05.010_bb0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev-genom-090314-050016","article-title":"Mendelian randomization: new applications in the coming age of hypothesis-free causality","volume":"16","author":"Evans","year":"2015","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.schres.2021.05.010_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pnpbp.2018.05.007","article-title":"Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials","volume":"86","author":"Fabbri","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mp.2014.56","article-title":"Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients","volume":"20","author":"Frank","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0170","first-page":"87","article-title":"Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate","volume":"77","author":"Fuller","year":"1992","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0175","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ajmg.b.31192","article-title":"Hypomethylation of the serotonin receptor type-2A gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder","volume":"156B","author":"Ghadirivasfi","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4161\/epi.5.6.12228","article-title":"Tissue specific DNA methylation of CpG islands in normal human adult somatic tissues distinguishes neural from non-neural tissues","volume":"5","author":"Ghosh","year":"2010","journal-title":"Epigenetics"},{"issue":"10","key":"10.1016\/j.schres.2021.05.010_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103026","article-title":"DNA methylation as a biomarker of treatment response variability in serious mental illnesses: a systematic review focused on bipolar disorder, schizophrenia, and major depressive disorder","volume":"19","author":"Goud Alladi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.schres.2021.05.010_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","article-title":"Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis","volume":"26","author":"Gressier","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/bioinformatics\/btf869","article-title":"Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions","volume":"19","author":"Hahn","year":"2003","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0205","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1006304","article-title":"The path to personalized medicine","volume":"363","author":"Hamburg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2021.05.010_bb0210","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58430","article-title":"DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia","volume":"10","author":"Hannon","year":"2021","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ije\/dyr225","article-title":"Commentary: the seven plagues of epigenetic epidemiology","volume":"41","author":"Heijmans","year":"2012","journal-title":"Int. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.schres.2021.05.010_bb0220","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrg3270","article-title":"DNA methylation profiling in the clinic: applications and challenges","volume":"13","author":"Heyn","year":"2012","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2021.05.010_bb0230","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ebiom.2017.04.002","article-title":"Is an early age at illness onset in schizophrenia associated with increased genetic susceptibility? Analysis of data from the Nationwide Danish Twin Register","volume":"18","author":"Hilker","year":"2017","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41576-018-0004-3","article-title":"DNA methylation-based biomarkers and the epigenetic clock theory of ageing","volume":"19","author":"Horvath","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/pgs.15.155","article-title":"Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response","volume":"17","author":"Huang","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv132","article-title":"Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis","volume":"19","author":"Huang","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.schres.2021.05.010_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15592294.2019.1644879","article-title":"Methodological challenges in constructing DNA methylation risk scores","volume":"15","author":"Huls","year":"2020","journal-title":"Epigenetics"},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0255","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neures.2013.08.004","article-title":"DNA methylation analysis of BDNF gene promoters in peripheral blood cells of schizophrenia patients","volume":"77","author":"Ikegame","year":"2013","journal-title":"Neurosci. Res."},{"issue":"7256","key":"10.1016\/j.schres.2021.05.010_bb0260","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder","volume":"460","author":"International Schizophrenia, C","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0265","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.mcn.2008.03.007","article-title":"HES1 regulates 5-HT1A receptor gene transcription at a functional polymorphism: essential role in developmental expression","volume":"38","author":"Jacobsen","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nn.4181","article-title":"Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex","volume":"19","author":"Jaffe","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0275","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2014.65","article-title":"Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia","volume":"39","author":"Jenkins","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0280","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0285","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2021.05.010_bb0290","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2147\/NDT.S164647","article-title":"COMT Val 108\/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia","volume":"14","author":"Kaneko","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2021.05.010_bb0295","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajp.2017.07.026","article-title":"Identification of genetic correlates of response to Risperidone: findings of a multicentric schizophrenia study from India","volume":"29","author":"Kaur","year":"2017","journal-title":"Asian J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030632","article-title":"Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia","volume":"18","author":"Kinoshita","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0310","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tig.2012.04.002","article-title":"Epigenetics of major psychosis: progress, problems and perspectives","volume":"28","author":"Labrie","year":"2012","journal-title":"Trends Genet."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0315","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/524110","article-title":"DNA methylation signatures within the human brain","volume":"81","author":"Ladd-Acosta","year":"2007","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0320","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0325","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pnpbp.2003.09.024","article-title":"Combination of \u201catypical\u201d antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder","volume":"28","author":"Lerner","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0330","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u2018response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2021.05.010_bb0335","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.schres.2017.04.009","article-title":"Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes","volume":"192","author":"Li","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.05.010_bb0340","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fpsyt.2019.00058","article-title":"Association of serotonin2c receptor polymorphisms with antipsychotic drug response in schizophrenia","volume":"10","author":"Li","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41398-020-0763-4","article-title":"Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia","volume":"10","author":"Liang","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0350","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.npp.1300571","article-title":"Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy","volume":"30","author":"Lieberman","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.schres.2021.05.010_bb0355","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2021.05.010_bb0360","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neulet.2016.12.071","article-title":"DNA methylation and clinical response to antidepressant medication in major depressive disorder: a review and recommendations","volume":"669","author":"Lisoway","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0365","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/14656566.1.7.1441","article-title":"Pharmacology and clinical experience with risperidone","volume":"1","author":"Love","year":"2000","journal-title":"Expert. Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0370","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/epi.24362","article-title":"Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies","volume":"8","author":"Lowe","year":"2013","journal-title":"Epigenetics"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0375","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ddr.21686","article-title":"Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients","volume":"81","author":"Maffioletti","year":"2020","journal-title":"Drug Dev. Res."},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0380","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.schres.2021.05.010_bb0385","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/mp.2011.146","article-title":"Pharmacogenetics in psychiatry: translating research into clinical practice","volume":"17","author":"Malhotra","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0390","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1192\/bjp.178.1.86","article-title":"Olanzapine: concordant response in monozygotic twins with schizophrenia","volume":"178","author":"Mata","year":"2001","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020118","article-title":"Integrative genomic-epigenomic analysis of clozapine-treated patients with refractory psychosis","volume":"14","author":"Mayen-Lobo","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.schres.2021.05.010_bb0400","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/nn.3816","article-title":"Analytical tools and current challenges in the modern era of neuroepigenomics","volume":"17","author":"Maze","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0405","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1096\/fj.11-202069","article-title":"Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset","volume":"26","author":"Melas","year":"2012","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0410","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2049-9256-1-19","article-title":"Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis","volume":"1","author":"Melka","year":"2013","journal-title":"J. Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.schres.2021.05.010_bb0420","first-page":"900","article-title":"New trends in the treatment of schizophrenia","volume":"16","author":"Meltzer","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0425","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r11852","article-title":"Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis","volume":"79","author":"Mentzel","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2021.05.010_bb0430","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpsychires.2018.02.018","article-title":"DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: a preliminary study","volume":"100","author":"Miura","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0435","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/jamapsychiatry.2016.0144","article-title":"Association of DNA methylation differences with schizophrenia in an epigenome-wide association study","volume":"73","author":"Montano","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0440","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0447.2001.00401.x","article-title":"Familial occurrence of tardive dyskinesia","volume":"104","author":"Muller","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"issue":"18","key":"10.1016\/j.schres.2021.05.010_bb0445","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00213-014-3515-4","article-title":"Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients","volume":"231","author":"Nikolac Perkovic","year":"2014","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0450","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcn.12622","article-title":"DNA methylation of membrane-bound catechol-O-methyltransferase in Malaysian schizophrenia patients","volume":"72","author":"Nour El Huda","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0455","first-page":"109","article-title":"Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort","volume":"19","author":"O\u2019Connell","year":"2019","journal-title":"Pharm. J."},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0460","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.biopsych.2014.06.016","article-title":"DNA modification study of major depressive disorder: beyond locus-by-locus comparisons","volume":"77","author":"Oh","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0465","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41467-018-03073-7","article-title":"Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging","volume":"9","author":"Oh","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.schres.2021.05.010_bb0470","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pnpbp.2017.10.004","article-title":"DNA methylation and antipsychotic treatment mechanisms in schizophrenia: progress and future directions","volume":"81","author":"Ovenden","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0475","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","article-title":"Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection","volume":"50","author":"Pardinas","year":"2018","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132992","article-title":"Differences in the epigenetic regulation of cytochrome P450 genes between human embryonic stem cell-derived hepatocytes and primary hepatocytes","volume":"10","author":"Park","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0485","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40273-017-0515-3","article-title":"The cost of relapse in schizophrenia","volume":"35","author":"Pennington","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.schres.2021.05.010_bb0490","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","article-title":"Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis","volume":"162","author":"Perkins","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"7299","key":"10.1016\/j.schres.2021.05.010_bb0495","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nature09230","article-title":"Epigenetics as a unifying principle in the aetiology of complex traits and diseases","volume":"465","author":"Petronis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.schres.2021.05.010_bb0500","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.pharmtox.48.113006.094731","article-title":"Epigenetics and complex disease: from etiology to new therapeutics","volume":"48","author":"Ptak","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0505","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.ejhg.5201418","article-title":"An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray","volume":"13","author":"Qin","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0510","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/pgs.09.171","article-title":"Classical twin design in modern pharmacogenomics studies","volume":"11","author":"Rahmioglu","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0515","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/FPC.0000000000000314","article-title":"Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia","volume":"28","author":"Rajagopal","year":"2018","journal-title":"Pharmacogenet. Genomics"},{"issue":"1\u20133","key":"10.1016\/j.schres.2021.05.010_bb0520","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2014.09.038","article-title":"Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial","volume":"160","author":"Ramsey","year":"2014","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0525","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2217\/pgs.14.54","article-title":"Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group","volume":"15","author":"Ramsey","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0530","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10545-018-0146-7","article-title":"The functional genomics laboratory: functional validation of genetic variants","volume":"41","author":"Rodenburg","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.schres.2021.05.010_bb0535","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/NDT.S228103","article-title":"The CYP2C19*2 and CYP2C19*17 polymorphisms influence responses to clozapine for the treatment of schizophrenia","volume":"16","author":"Rodrigues-Silva","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2021.05.010_bb0540","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2015.07.022","article-title":"Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology","volume":"101","author":"Rojo","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.schres.2021.05.010_bb0545","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0550","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/13102818.2014.933501","article-title":"Whole genome methylation analyses of schizophrenia patients before and after treatment","volume":"28","author":"Rukova","year":"2014","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0555","first-page":"146","article-title":"The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis","volume":"17","author":"Sacchetti","year":"2017","journal-title":"Pharm. J."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0560","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41398-018-0230-7","article-title":"Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort","volume":"8","author":"Santoro","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"5568","key":"10.1016\/j.schres.2021.05.010_bb0565","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1126\/science.1070532","article-title":"Schizophrenia: diverse approaches to a complex disease","volume":"296","author":"Sawa","year":"2002","journal-title":"Science"},{"issue":"7510","key":"10.1016\/j.schres.2021.05.010_bb0570","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics, C","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0575","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajhg.2015.05.014","article-title":"Improving phenotypic prediction by combining genetic and epigenetic associations","volume":"97","author":"Shah","year":"2015","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.143","article-title":"Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients","volume":"7","author":"Shi","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2021.05.010_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000895","article-title":"DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons","volume":"2","author":"Siegmund","year":"2007","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0590","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ajmg.b.32278","article-title":"DNA extracted from saliva for methylation studies of psychiatric traits: evidence tissue specificity and relatedness to brain","volume":"168B","author":"Smith","year":"2015","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"11","key":"10.1016\/j.schres.2021.05.010_bb0595","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1517\/17425255.2015.1075003","article-title":"Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update","volume":"11","author":"Sriretnakumar","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.schres.2021.05.010_bb0600","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.10","article-title":"Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes","volume":"6","author":"Stevenson","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2021.05.010_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020212","article-title":"The genetics of schizophrenia","volume":"2","author":"Sullivan","year":"2005","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0610","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrg2341","article-title":"DNA methylation landscapes: provocative insights from epigenomics","volume":"9","author":"Suzuki","year":"2008","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb2005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/epi-2017-0086","article-title":"Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response","volume":"10","author":"Swathy","year":"2018","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0625","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/138920021602150713114159","article-title":"Epigenetic regulation of cytochrome P450 enzymes and clinical implication","volume":"16","author":"Tang","year":"2015","journal-title":"Curr. Drug Metab."},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0630","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1017\/S1461145713001442","article-title":"Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia","volume":"17","author":"Tang","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2021.05.010_bb0635","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpsychires.2018.07.012","article-title":"Combinatorial pharmacogenomics and improved patient outcomes in depression: treatment by primary care physicians or psychiatrists","volume":"104","author":"Tanner","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0640","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hup.2519","article-title":"Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine","volume":"31","author":"Taylor","year":"2016","journal-title":"Hum. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0645","first-page":"185","article-title":"Pharmacogenetic analysis of functional glutamate system gene variants and clinical response to clozapine","volume":"2","author":"Taylor","year":"2017","journal-title":"Mol. Neuropsychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.05.010_bb0650","first-page":"127","article-title":"Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia","volume":"28","author":"Terzic","year":"2016","journal-title":"Psychiatr. Danub."},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0655","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mp.2013.74","article-title":"Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis","volume":"19","author":"Tiwari","year":"2014","journal-title":"Mol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2021.05.010_bb0660","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.schres.2015.08.002","article-title":"Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment","volume":"168","author":"van de Bilt","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.05.010_bb0665","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2018.07.002","article-title":"Impact of antipsychotic treatment on methylation status of Interleukin-6 [IL-6] gene in schizophrenia","volume":"104","author":"Venugopal","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0670","first-page":"210","article-title":"Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions","volume":"26","author":"Viana","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"8993","key":"10.1016\/j.schres.2021.05.010_bb0675","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(96)91594-9","article-title":"Monozygotic twins concordant for response to clozapine","volume":"347","author":"Vojvoda","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2021.05.010_bb0680","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.psychres.2018.02.055","article-title":"Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication","volume":"279","author":"Walden","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2021.05.010_bb0685","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3389\/fpsyt.2019.00633","article-title":"Association study of KCNH7 polymorphisms and individual responses to risperidone treatment in schizophrenia","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2021.05.010_bb0690","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/schbul\/sbx007","article-title":"Polygenic risk score for schizophrenia and treatment-resistant schizophrenia","volume":"43","author":"Wimberley","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2021.05.010_bb0695","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fgene.2012.00118","article-title":"Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder","volume":"3","author":"Wray","year":"2012","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0700","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.cell.2011.12.035","article-title":"Base-resolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome","volume":"148","author":"Xie","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0705","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2215-0366(18)30049-X","article-title":"Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study","volume":"5","author":"Yu","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.05.010_bb0710","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/YCO.0000000000000417","article-title":"New findings in pharmacogenetics of schizophrenia","volume":"31","author":"Zai","year":"2018","journal-title":"Curr. Opin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2021.05.010_bb0715","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/schbul\/sbv116","article-title":"Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis","volume":"41","author":"Zhang","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2021.05.010_bb0720","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ajp.2018.17121363","article-title":"Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis","volume":"176","author":"Zhang","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2021.05.010_bb0725","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/epi-2019-0349","article-title":"A risk prediction model of DNA methylation improves prognosis evaluation and indicates gene targets in prostate cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Epigenomics"},{"key":"10.1016\/j.schres.2021.05.010_bb0730","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neulet.2018.08.002","article-title":"Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients","volume":"683","author":"Zhou","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2021.05.010_bb0735","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2019.00177","article-title":"Genetic association of olanzapine treatment response in Han Chinese schizophrenia patients","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421001705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421001705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:43:09Z","timestamp":1760298189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421001705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":146,"alternative-id":["S0920996421001705"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2021.05.010","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}